Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Color On PCSK9 Inhibitors Previews Commercial Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

The sponsors of the PCSK9 inhibitor class are getting lots of data boxes ticked off with the results presented at the American College of Cardiology, but it’s still largely a waiting game as investors, practitioners and patients wait for regulatory submissions and outcomes trials. New details on doses and devices preview commercial battle between Amgen’s evolocumab and Sanofi/Regeneron’s alirocumab.

You may also be interested in...



Statin Labeling Changes Include Class Warning About Glucose Effects

All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.

Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients

Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.

Publisher’s Spotlight: Shortlist Revealed For The 2021 Citeline Awards

From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research. 

Topics

Related Companies

UsernamePublicRestriction

Register

PS077035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel